In recent years, with the intensification of aging and the continuous enhancement of people's health awareness, the support of a series of favorable policies is promoting the rapid development of
the biomedical industry.
It is worth noting that with the rapid development of biomedicine, the production scale of the traditional biological engineering industry has expanded significantly, and the demand for related equipment to support the development of biological engineering has also begun to grow
.
Pharmaceutical machinery companies are accelerating the creation of biological engineering technology strength! (Image source: Pharmaceutical Network)
In this context, the bioengineering solutions and stand-alone business segments have developed rapidly, and pharmaceutical machinery companies have also ushered in more opportunities
.
It is understood that in 2021, through the semi-annual report of listed pharmaceutical machinery companies, it can be clearly seen that the performance of the bioengineering sector is very bright
.
For example, Chutian Technology, Bioengineering Solutions and Stand-alone business segments have developed rapidly, with revenue increasing by 255.
41%
year-on-year.
In the first half of 2021, Dongfulong also achieved revenue of 400 million yuan in the sector, accounting for 22.
13% of total revenue, an increase of more than 600%
year-on-year.
In addition, Canaan Technology also mentioned that with the expansion of the scale of innovative drugs in the biological industry, the company's biologics innovative pharmaceutical pharmaceutical water equipment and pharmaceutical compounding system engineering business will continue to become the main driving force
for the company's performance growth.
From the overall point of view, the bioengineering sector has become a major driving force
for many pharmaceutical machinery companies to achieve performance growth.
It is worth noting that at present, in order to further meet the needs of biopharmaceuticals and expand new performance growth points, many pharmaceutical machinery companies are still increasing the layout of the bioengineering field
.
For example, Dongfulong has been deeply cultivated in the field of biological engineering for many years, and the company's main products and services of biological engineering include bioreactors, biological wastewater inactivation, separation and purification (ultrafiltration, chromatography, etc.
) and other fields, which can not only provide customers with process equipment, but also provide customers with overall solutions (process + equipment + engineering), biological process integration and other services
.
On April 20, Dongfulong's 2021 annual performance briefing meeting, Dongfulong clearly stated that it will firmly focus on the development strategy of "systematic, internationalization and digitalization", and develop innovative products with forward-looking and independent intellectual property rights in the field of sterile injections, biological engineering and other pharmaceutical equipment, closely focusing on the production process and development direction of drugs, improving R&D efficiency, increasing innovation, and providing competitive and brand-influential overall system solutions for global pharmaceutical customers
。
In addition, on July 13, Dongfulong also issued the "Announcement on the Company's Issuance of Shares to Specific Targets and Approved by the Listing Review Center of the Shenzhen Stock Exchange"
.
It is understood that the total amount of funds raised by Dongfulong's issuance of shares to specific targets does not exceed 3.
2 billion yuan (including this number), and after deducting the issuance costs, the raised funds are intended to be used for the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, the zhejiang Dongfulong Biotechnology Co.
, Ltd.
life science industrialization base project, and supplementary working capital
.
At present, Chutian Technology is also improving its strength
in the field of biological engineering technology in a variety of ways.
It is reported that after continuing to increase investment in the field of biological engineering technology, technological innovation achievements and performance have grown significantly and rapidly
in recent years.
According to Chutian Technology's 2022 interim report, the revenue related to bioengineering solutions and stand-alone business increased by 191.
29%
year-on-year.
At present, Chutian Technology has basically completed the layout
of the whole industrial chain from the preparation equipment of the front-end of biopharmaceuticals to the production equipment of gene and cell therapy drugs.
For the future development of the biological engineering sector, Chutian Technology said that this is the focus of the company's development, and it will become an important part of
the company's operating performance in the future.
It has been laid out: disposable bioreactors, disposable dispensing systems, ultrafiltration chromatography purification, stainless steel reactors and fillers
.
Culture media, packaging materials and other products, the company is also planning the layout, and strive to complete the layout
within a certain period of time in the future.
In general, the bioengineering sector has become a major driving force
for many pharmaceutical machinery companies to achieve performance growth.
Therefore, it is not surprising that many companies continue to increase their
layout.
The industry expects that with the rapid development of biomedicine, the production scale of the traditional biological engineering industry has expanded significantly, and higher requirements have been put forward for technological transformation and upgrading, while the demand for equipment in the field of biological engineering will continue to expand, and a large number of enterprises in the future will continue to usher in a favorable
situation.
